Financial Performance - Second quarter sales were 870.0million,down0.80.79, a decrease of 2.2% compared to 2024, while adjusted EPS was 0.83,anincreaseof2.53.60 and 3.68,withsalesforecastedtobeflattoup4194.9 million, up from 190.8millioninthesameperiodof2024,representingagrowthof1.695.9 million for the three months ended January 31, 2025, compared to 98.7millioninthesameperiodlastyear[38]−AdjusteddilutedEPSforthethreemonthsendedJanuary31,2025,was0.83, up from 0.81intheprioryear[39]−TheadjustedEBITDAforthesixmonthsendedJanuary31,2025,was327.3 million, an increase from 311.9millionintheprioryear[38]SegmentPerformance−ThecompanygeneratedsalesgrowthinAftermarket(up4.0870.0 million for the three months ended January 31, 2025, down 0.8% from 876.7millioninthesameperiodof2024[28]−TheIndustrialSolutionssegmentsawa3.7253.7 million for the three months ended January 31, 2025, compared to 263.4millionin2024[28]−LifeSciencessegmentnetsalesincreasedby9.268.8 million for the three months ended January 31, 2025, compared to 63.0millionin2024[28]−TheLifeSciencessegmentshowedastrongperformancewitha12.885 million and 100million,withfreecashflowconversionexpectedbetween8571.5 million, compared to 65.8millioninthesameperiodlastyear[38]−Thecashconversionratioimprovedto74.4765.8 million from 782.5million,areductionof2.52,961.3 million as of January 31, 2025, compared to $2,914.3 million on July 31, 2024, reflecting a growth of 1.6%[21] - Total company revenue increased by 2.7% for the six months ended January 31, 2025, with a notable growth of 5.6% in the U.S./CA region[32]